Common questions
Ipamorelin questions, answered from the literature
Direct, cited answers to what people actually ask — about bone, IGF-1, the CJC-1295 pairing, appetite, and where the human evidence stands.
Does ipamorelin increase IGF-1?
Not consistently in short studies. In a 15-day rat bone study, subcutaneous ipamorelin raised the longitudinal bone-growth rate dose-dependently with no change in total IGF-1 [4]. Sustained or combination protocols can raise IGF-1 downstream of the growth-hormone pulse [13], but the systemic IGF-1 response is context-dependent and was absent in several short rodent experiments [4].
Does ipamorelin build muscle?
No controlled human muscle data exist. In animals, ipamorelin combined with a glucocorticoid raised maximum tetanic muscle tension in a steroid muscle-loss model [7], and a 2026 review reported the CJC-1295 + ipamorelin combination improved tetanic tension in mice [15]. These are animal findings; the human muscle-building claim is not established by any controlled trial [3].
Is ipamorelin good for bones?
In rats, yes — measurably. Subcutaneous ipamorelin at 18, 90, and 450 micrograms a day raised the longitudinal bone-growth rate from 42 to 52 micrometers a day dose-dependently [4], and 12 weeks of continuous dosing increased tibial and vertebral bone mineral content [8]. It also partly rescued steroid-weakened bone [7]. All of this skeletal evidence is preclinical; no human bone outcome has been tested [3].
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively releases growth hormone by activating the ghrelin receptor (GHS-R1a) on pituitary cells [1]. Its defining trait is selectivity — it raises growth hormone without raising ACTH or cortisol, even at high doses [1]. It is a research peptide, not an approved drug [3].
What does ipamorelin do for you?
In the body, ipamorelin triggers a discrete pulse of growth hormone via the ghrelin receptor [1]. In animals that translates to faster longitudinal bone growth [4] and added bone mineral content [8]. In humans, the evidence is thin and largely negative — its one Phase 2 trial missed its endpoint [3] — so claims of human benefit are not supported by controlled data.
What is ipamorelin peptide?
It is a five-amino-acid synthetic peptide that mimics the hunger hormone ghrelin at its receptor to release growth hormone [1]. The Aib building block at position one gives it metabolic stability [5]. It is described as the first selective growth-hormone secretagogue because it releases growth hormone cleanly, without the cortisol and prolactin rises seen with older GH-releasing peptides [1].
What are the risks of ipamorelin?
The biggest risk is the unknown: no long-term human safety data exist, and its only Phase 2 trial (n=114) was a short seven-day IV course [3]. Mechanistic cautions apply to active cancer (IGF-1 is a mitogen) [11], diabetes (mixed glucose effects) [9], and heart disease (a class-level cardiotoxicity signal in a related agonist) [6]. Research-grade material also has unverified purity [3].
Does ipamorelin reduce belly fat?
There is no human evidence that ipamorelin reduces belly fat. In a 2024 ferret study, intraperitoneal ipamorelin reduced cisplatin-induced body-weight loss by about 24 percent — a weight-preserving effect, not fat loss [16]. Mouse data actually show raised fat-pad weight and leptin [10]. Any "fat loss" reported by users is anecdotal and confounded by diet and training [3].
What are the downsides of ipamorelin?
The central downside is that it does not have proven human benefit — its lone Phase 2 trial missed its endpoint [3]. Reported adverse effects (anecdotal) include a post-injection flush, increased hunger, tingling, mild water retention, and injection-site irritation. Mechanistic concerns include glucose effects [9] and a class-level cardiac signal in a related compound [6].
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product to discontinue; its clinical development stalled because its only Phase 2 trial for postoperative ileus missed its primary endpoint (25.3 vs 32.6 hours, p=0.15) and no further program followed [3]. Separately, in 2024 the FDA removed ipamorelin acetate from Category 2 of the interim 503A bulk-substances list, tightening compounding-pharmacy access [3].
What does CJC-1295 and ipamorelin do?
They raise growth hormone through two different doorways — CJC-1295 on the GHRH receptor, ipamorelin on the ghrelin receptor — which is the rationale for combining them [1]. In animals, the combination improved tetanic muscle tension in a steroid muscle-loss model [15]. No controlled human trial has tested the pairing for any outcome [3].
How does CJC-1295 ipamorelin work?
CJC-1295 stimulates the GHRH receptor while ipamorelin stimulates the ghrelin receptor (GHS-R1a); the two pathways converge on pituitary growth-hormone release and are complementary [1]. The idea is a larger or more sustained growth-hormone signal than either alone, but this synergy is inferred from single-agent pharmacology, not demonstrated in a human combination trial [3].
How much CJC-1295 ipamorelin should I take?
No validated human dose exists, and this site does not provide one. The combination has never been tested in a controlled human trial [3], and community subcutaneous protocols have no peer-reviewed human dosing basis — they are anecdotal, not recommended [3]. What the literature establishes is mechanism [1] and a roughly two-hour half-life [2], not a dose to take.
Does CJC-1295 ipamorelin work?
Evidence is limited to animal studies. A 2026 narrative review found CJC-1295 with ipamorelin improved maximum tetanic tension in a glucocorticoid-induced muscle-loss model in mice, while noting the evidence base is limited and not established in humans [15]. No controlled human trial supports the combination for any outcome [3].
How to reconstitute CJC-1295 ipamorelin 5mg?
Ipamorelin is supplied as a lyophilized (freeze-dried) powder and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and repeated freeze-thaw, so solution is typically refrigerated [2]. These are general research-supply handling notes, not a clinical preparation or dosing instruction, and research-grade purity is unverified [3].
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin's terminal half-life is approximately two hours, with the growth-hormone pulse it triggers peaking near 40 minutes after a dose [2]. Systemic exposure is therefore short-lived. In rats, plasma clearance is roughly five-fold lower than GHRP-6, with 60 to 80 percent of a dose recovered intact in bile and urine [5].
Does ipamorelin make you hungry?
It can, by mechanism. Ipamorelin acts on the ghrelin receptor, and ghrelin-receptor agonists activate the brain's appetite centers and induce feeding in animals [12]. Users often report increased appetite after a dose, described as milder than with GHRP-6 but still noticeable [12]. This is a class-level orexigenic signal built into how the peptide works.
Will I gain weight on ipamorelin?
There is no human weight-outcome data. In mice, ipamorelin raised fat-pad weight and leptin, partly independent of growth hormone [10], and its appetite-raising mechanism could increase intake [12]. Its one human trial was a short perioperative course not designed to measure weight [3]. Any weight change is unverified and confounded by diet and activity.
Does ipamorelin increase appetite?
Yes, by mechanism it can. As a ghrelin-receptor agonist, ipamorelin engages the same pathway the hunger hormone uses; central administration of ghrelin and GH secretagogues induces feeding in rats [12]. Community reports describe an appetite uptick after injection, generally milder than with GHRP-6 [12]. It is a recognized class-level effect, not a clinical finding in humans.
What does ipamorelin peptide do?
It releases a pulse of growth hormone by selectively activating the ghrelin receptor on pituitary cells, without raising cortisol or prolactin [1]. In animals this drives faster bone growth [4] and added bone mineral content [8]. In humans, its evidence is limited and its one efficacy trial missed [3], so its human effects are not established by controlled data.
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks near 40 minutes after a dose in humans [2]. For the effects people care about, the picture is anecdotal — community reports describe sleep changes within one to two weeks, with body-composition shifts noted only over weeks to months, all unverified [3]. No controlled human onset data exist for those outcomes.
Does ipamorelin cause water retention?
Mild water retention is occasionally reported by users (anecdotal), described as milder than with older GHRP compounds and often settling with continued use [3]. Mechanistically it is plausible: growth-hormone excess is associated with sodium and water retention [6]. No controlled human study has measured fluid balance on ipamorelin at research-use doses [3].